Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 4/20 | 0.37 |
| ▸ | CFTR | P13569 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22235514 | 0.80 | GABRA1 (0.35) | KDM4ESMN1; SMN2KMT2ALMNAMAPT | |
| SCHEMBL22235409 | 0.80 | GABRA1 (0.35) | KDM4ESMN1; SMN2KMT2ALMNAMAPT | |
| SCHEMBL22235343 | 0.80 | GABRA1 (0.35) | KDM4ESMN1; SMN2KMT2ALMNAMAPT | |
| SCHEMBL29728904 | 0.80 | GABRA1 (0.35) | KDM4ESMN1; SMN2KMT2ALMNAMAPT | |
| SCHEMBL22236137 | 0.78 | GABRG2 (0.41) | KDM4EKMT2ALMNAMEN1TSHR | |
| SCHEMBL29728940 | 0.77 | PDK2 (0.35) | KDM4EKMT2ALMNAMAPTMEN1 | |
| SCHEMBL22235398 | 0.77 | PDK2 (0.35) | KDM4EKMT2ALMNAMAPTMEN1 | |
| SCHEMBL22236290 | 0.73 | ACHE (0.35) | P2RX7KDM4ESMN1; SMN2KMT2ATSHR | |
| SCHEMBL22235440 | 0.72 | ALDH1A1 (0.34) | KDM4EKMT2AMAPTMEN1NPC1 | |
| SCHEMBL22235323 | 0.72 | ALDH1A1 (0.34) | KDM4EKMT2AMAPTMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125771-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-04-28 | — | — | US | disclosed |
| CN-113825756-A | Substituted polycyclic carboxylic acids, analogs thereof, and methods of use thereof | 爱彼特生物制药公司 | 2021-12-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125771-A1 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, HDGF | MAPK8 2637/4885CFTR 1500/4885P2RX7 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.